Since the inception of cancer immunotherapy, the field of cancer treatment has experienced remarkable advancements. However, despite these remarkable strides, certain persistent limitations continue to impede the clinical effectiveness of this approach. In recognition of these challenges, our laboratory is presently wholeheartedly committed to the development of Smart Biomaterials (SBMs) through the utilization of adoptive cellular therapy (ACT).
 

   Our central objective revolves around the augmentation of nanoparticles' therapeutic efficiency. This objective is accomplished by meticulously introducing precise modifications to their surfaces, employing a diverse repertoire of immune boosters (IBs). Through this meticulous fine-tuning of the SBMs' functionality, our ultimate aim is to realize the highest conceivable level of therapeutic efficacy. Additionally, based on our projections, we anticipate that the optimized IBs-SBMs will demonstrate exceptional stability, even when subjected to prolonged storage periods. This envisioned stability not only guarantees the preservation of their therapeutic properties but also streamlines the storage process itself, facilitating convenience and accessibility.
 

   Within the purview of this study, we introduce groundbreaking strategies that effectively synergize the blockade of immune tolerance with the augmentation of immune activity. By harmoniously integrating these approaches, we lay the foundational framework necessary to unlock the untapped potential of therapeutic vaccines and maximize their overall effectiveness.